Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 - Proof of Concept, Safety, and Efficacy Study
Sponsor: Glia, LLC
Listed as NCT02656394, this PHASE2 trial focuses on Ocular Surface Disease and remains completed. Sponsored by Glia, LLC, it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2021 — Apr 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jun 2019 — Aug 2019 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Glia, LLC
For direct contact, visit the study record on ClinicalTrials.gov .